Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers
To investigate in situ-in vitro molecular correspondence and the relationship between in vitro and patient response to temozolomide (TMZ) Overall design: Gene expression profiling analysis using data obtained from RNA-seq of 24 different GBM cell cultures